Technology evaluation: huN901-DM1, ImmunoGen

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 4, 2005, Pages 394-401

  Smith, Suzanne V ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BB 10901; BIVATUZUMAB MERTANSINE; CANTUZUMAB MERTANSINE; CD56 ANTIGEN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOFOS; J 591; MAYTANSINE; METHOTREXATE; MLN 2704; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OBLIMERSEN; PACLITAXEL; PRODRUG; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; BIOTECHNOLOGY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART DISEASE; HUMAN; HYPERESTHESIA; IC 50; INFUSION SITE REACTION; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MENINGITIS; MULTIPLE MYELOMA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPHILIA; NONHUMAN; PATENT; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; THYROID DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; CARCINOMA, SMALL CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; LUNG NEOPLASMS; PRODRUGS;

EID: 23344439255     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 193322 Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blatter WA, MacKenzie SJ, Goldmacher VS CANCER RES 1992 52 1 127-131
2. 255239 Cure of human small cell lung cancer xenografts in SCID mice by a hN901-maytansinoid immunoconjugate. Liu C, Bourret LA, Derr SM, Widdison WC, Lambert JM, Blattler WA, Chari RV PROC AM ASSOC CANCER RES 1997 38 Abs 190
3. 362875 Dose-response of the anti-tumor effect of huN901-DM1 against human small cell lung cancer xenografts. Chari RV, Derr SM, Steeves RM, Widdison WC PROC AM ASSOC CANCER RES 2000 41 Abs 4405
4. 365353 British Biotech and ImmunoGen enter huN901-DM1 collaboration. British Biotech plc PRESS RELEASE 2000 May 05
5. 365354 British Biotech and ImmunoGen enter huN901-DM1 collaboration. ImmunoGen Inc PRESS RELEASE 2000 May 05
6. 369012 Eradication of prostate cancer xenografts by immunoconjugates targeting the extracellular domain of prostate-specific membrane antigen (PSMA). Yao D, Richstone L, Kim S, Liu H, Chari RJ, Bander NH PROC AM SOC CLIN ONCOL 2000 19 Abs 1329
7. 390071 Preclinical development of huN901-DM1: A tumor-activated prodrug directed against small cell lung cancer. Chari R, Steeves VJ, Rita M, Hongsheng X, Wayne C NCI EORTC SYMP NEW DRUGS CANCER THER 2000 11 Abs 118
8. 390989 The development of antibody delivery systems to target cancer with highly potent maytansinoids. Liu C, Chari RV EXPERT OPIN INVEST DRUGS 1997 6 2 169-172
9. 390990 Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blattler WA, Chari RV PROC NATL ACAD SCI USA 1996 93 16 8618-8623
10. 403950 Technology evaluation: C242-DM1, ImmunoGen Inc. Smith S CURR OPIN MOL THER 2001 3 2 198-203
11. 410981 British Biotech and ImmunoGen begin phase I/II trial of BB-10901 in SCLC. ImmunoGen Inc PRESS RELEASE 2001 May 29
12. 451697 ImmunoGen Inc and British Biotech plc announce presentation of data from ongoing phase I/II clinical study of huN901-DM1/BB-10901 at the 2002 meeting of the American Society of Clinical Oncology. ImmunoGen Inc PRESS RELEASE 2002 May 20
13. 452678 Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Fossela FV, Tolcher A, Elliot M, Lambert JM, Lu R, Zinner R, Lu C, Oh Y, Forouzesh B, McCreary H, Rowinsky EK et al PROC AM SOC CLIN ONCOL 2002 21 1 Abs 1232
14. 456071 Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Chari RV ADV DRUG DELIV REV 1998 31 89-104
15. 460639 ImmunoGen and British Biotech start new phase I study of huN901-DM1. ImmunoGen Inc PRESS RELEASE 2002 August 08
16. 471468 A phase I and pharmacokinetic study of BB10901, a maytansinoid immunoconjugate, in CD56 expressing tumors. Tolcher A, Forouzesh B, McCreery H, Zinner R, Clinch Y, Banington P, Lambert J, Howard M, Rowinsky E, Fossella F AACR NCI EORTC MOL TARGETS CANCER THER 2002 13 Abs 509
17. 478213 ImmunoGen Inc reports second quarter 2003 results. ImmunoGen Inc PRESS RELEASE 2003 February 06
18. 516432 In vitro and in vivo antitumor activity of the maytansinoid immunoconjugate BB-10901 (huN901-DM1) on CD56+ multiple myeloma cells. Tassone P, Gozzini A, Goldmacher VS, Shammas MA, Shringarpure R, Catley L, Hayashi T, Hideshima T, Chauhan D, Anderson KC, Munshi N, Anderson KC BLOOD 2003 102 11 Abs 2554
19. 518222 Progress in immunoconjugate cancer therapeutics. Payne G CANCER CELL (ONLINE) 2003 3 3 207-212
20. 518592 ImmunoGen to advance cantuzumab and huN901-DM1 development alone. ImmunoGen Inc PRESS RELEASE 2004 January 08
21. 523173 ImmunoGen Inc reports fiscal year 2004 second quarter financial results. ImmunoGen Inc PRESS RELEASE 2004 February 12
22. 548074 ImmunoGen Inc announces publication of preclinical data on the anticancer activity of huN901-DM1 in multiple myeloma. ImmunoGen Inc PRESS RELEASE 2004 July 08
23. 548200 In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′- (3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC CANCER RES 2004 64 13 4629-4636
24. 550991 Immunotoxins and antibody-drug conjugates. Goldmacher VS, Blattler WA, Lambert JM, Chari RV In: BIOMEDICAL ASPECTS DRUG TARGETING Muzykantov VR, Torchilin VP (Eds), Kluwer Academie Publisher, Boston, MA, USA (2002) 291-309
25. 569037 ImmunoGen Inc reports first quarter fiscal year 2005 financial results. ImmunoGen Inc PRESS RELEASE 2004 November 04
26. 575677 Technology evaluation: Cantuzumab mertansine (Immunogen). Smith SV CURR OPIN MOL THER 2004 6 6 666-674
27. 583108 Products. ImmunoGen Inc COMPANY WORLD WIDE WEB SITE 2004 December 28
28. 583259 Drug development pipeline: huN901-DM1. Vernalis plc COMPANY COMMUNICATION 2005 February 03
29. 584163 ImmunoGen, Inc. provides update on collaboration with Boehringer Ingelheim. ImmunoGen Inc PRESS RELEASE 2005 February 09
30. 584632 Targeted molecules in small cell lung cancer. Murray N, Salgia R, Fossella FV SEMIN ONCOL 2004 31 1 Suppl 1 106-111
31. 589884 Humanization of murine monoclonal antibodies through variable domain resurfacing. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blattler WA, Rees AR, Guild BC PROC NATL ACAD SCI USA 1994 91 3 969-973
32. 589886 Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N CANCER TREAT REV 2004 30 4 359-368
33. 589888 Recent advances in management of small-cell lung cancer. Chua YJ, Steer C, Yip D CANCER TREAT REV 2004 30 6 521-543
34. 590024 Molecular abnormalities in lung cancer. Salgia R, Skarin AT J CLIN ONCOL 1998 16 3 1207-1217
35. 590026 Molecular pathogenesis of lung cancer. Fong KM, Sekido Y, Minna JD J THORAC CARDIOVASC SURG 1999 118 6 1136-1152
36. 590031 Treatment and outcomes for elderly patients with small cell lung cancer. Stephens RJ, Johnson DH DRUGS AGING 2000 17 3 229-247
37. 590033 Characterization of an antigen expressed by human natural killer cells. Griffin JD, Hercend T, Beveridge R, Schlossman SF J IMMUNOL 1983 130 6 2947-2951
38. 590047 Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Patel K, Moore SE, Dickson G, Rossell RJ, Beverley PC, Kemshead JT, Walsh FS INT J CANCER 1989 44 4 573-578
39. 590438 ImmunoGen announces achievement of milestone in collaboration with sanofi-aventis. ImmunoGen Inc PRESS RELEASE 2005 March 17
40. 592747 ImmunoGen submits IND for tumor-activated prodrug. ImmunoGen Inc PRESS RELEASE 2005 March 31
41. 596688 Drug development piepline: AVE-9633. ImmunoGen Inc COMPANY COMMUNICATION 2005 April 20
42. 602058 ImmunoGen Inc reports initial phase II findings with its huN901-DM1 anticancer compound in the treatment of small-cell lung cancer; company's lead TAP compound demonstrates objective evidence of anticancer activity. ImmunoGen Inc PRESS RELEASE 2005 May 17
43. 602580 American Society of Clinical Oncology - 41st Annual Meeting (Part VII), Orlando, FL, USA. IDDB MEETING REPORT 2005 May 13-17
44. 602989 Phase II trial of BB-109901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. Fossella F, McCann J, Tolcher A, Xie H, Hwang L, Carr K, Berg K, Fram R PROC AM SOC CLIN ONCOL 2005 24 Abs 7159